Fidelity Investments
SPRO icon

Fidelity Investments’s Spero Therapeutics SPRO Stock Holding History

Fidelity Investments’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.33K Buy
1,100
+800
+267% +$1.09K ﹤0.01% 5293
2026
Q2 		$663 Buy
+300
New +$785 ﹤0.01% 5286
2025
Q4 		– Sell
-550
Closed -$1.03K – 5582
2025
Q3 		$1.03K Buy
+550
New +$1.21K ﹤0.01% 5013
2025
Q2 		– Sell
-5,056
Closed -$3.64K – 5493
2025
Q1 		$3.64K Buy
5,056
+767
+18% +$647 ﹤0.01% 4782
2024
Q4 		$4.42K Buy
4,289
+1,150
+37% +$1.37K ﹤0.01% 4688
2024
Q3 		$4.21K Buy
3,139
+250
+9% +$335 ﹤0.01% 4660
2024
Q2 		$3.76K Buy
2,889
+500
+21% +$754 ﹤0.01% 4621
2024
Q1 		$4.11K Buy
2,389
+2,200
+1,164% +$3.45K ﹤0.01% 4565
2023
Q4 		$278 Buy
+189
New +$225 ﹤0.01% 4853
2023
Q3 		– Sell
-4
Closed -$6 – 5500
2023
Q2 		$6 Buy
+4
New +$7 ﹤0.01% 5308
2022
Q3 		– Sell
-4,120
Closed -$3.05K – 5525
2022
Q2 		$3.05K Buy
4,120
+4,017
+3,900% +$11.7K ﹤0.01% 4468
2022
Q1 		$896 Buy
+103
New +$1.06K ﹤0.01% 4836
2021
Q2 		– Sell
-8,552
Closed -$126K – 4826
2021
Q1 		$126K Hold
8,552
– – ﹤0.01% 2892
2020
Q4 		$166K Sell
8,552
-2,200
-20% -$34.3K ﹤0.01% 2811
2020
Q3 		$120K Sell
10,752
-30,900
-74% -$366K ﹤0.01% 2766
2020
Q2 		$564K Sell
41,652
-57,300
-58% -$643K ﹤0.01% 2497
2020
Q1 		$800K Hold
98,952
– – ﹤0.01% 2367
2019
Q4 		$951K Sell
98,952
-71,636
-42% -$773K ﹤0.01% 2413
2019
Q3 		$1.81M Sell
170,588
-58,364
-25% -$615K ﹤0.01% 2291
2019
Q2 		$2.64M Sell
228,952
-160,300
-41% -$1.93M ﹤0.01% 2261
2019
Q1 		$4.99M Sell
389,252
-99,300
-20% -$1.05M ﹤0.01% 2082
2018
Q4 		$3M Sell
488,552
-129,654
-21% -$1.05M ﹤0.01% 2185
2018
Q3 		$6.5M Sell
618,206
-181,794
-23% -$2.11M ﹤0.01% 2066
2018
Q2 		$11.7M Hold
800,000
– – ﹤0.01% 1899
2018
Q1 		$11.4M Hold
800,000
– – ﹤0.01% 1925
2017
Q4 		$9.4M Buy
+800,000
New +$9.8M ﹤0.01% 1973

Other funds holding SPRO

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Employees Retirement System of Texas
Employees Retirement System of Texas Austin, Texas $12.2B AUM 27.55% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Fidelity Investments's SPRO Position: Q3 2026 in Review

Fidelity Investments increased its Spero Therapeutics (SPRO) stake by 267% in Q3 2026, buying an estimated $1.09K and bringing the position to 1,100 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #5293.

Fidelity Investments first reported a position in SPRO in Q4 2017 and has held it in 26 quarters since. The position peaked at $11.7M in Q2 2018. 32 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

  • Fidelity Investments held 1,100 shares of Spero Therapeutics worth $1.33K as of Q3 2026.
  • Fidelity Investments bought 800 Spero Therapeutics shares in Q3 2026, an estimated $1.09K.
  • Spero Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #5293 holding.
  • Fidelity Investments first reported a position in Spero Therapeutics in Q4 2017 and has held it in 26 quarters since.
  • Fidelity Investments's Spero Therapeutics position peaked at $11.7M in Q2 2018.
  • 32 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.